One of the company’s Xeljanz follow-ons is slowly emerging from stealth mode in atopic dermatitis.
Takeda gave biopharma’s M&A bill a big boost in 2018 but to see just how slow the year was, take a look at deal volumes.
The Spanish group shows again that there is a future in dermatology, but its Allergan deal really depends on the fate of one asset.